From Trials to Triumph—Glenmark Launches Game-Changing Immunotherapy

Glenmark Pharmaceuticals Ltd (NSE: GLEN.NS) has rolled out Tevimbra (tislelizumab) in India, which is a significant addition to the oncology portfolio of the company. Tevimbra is an immune checkpoint inhibitor of PD-1 that is intended to treat cancer like NSCLC and ESCC. The roll-out is in line with Glenmark's endeavor to bring innovative immuno-oncology therapies to Indian patients.

 

1. About Tevimbra

2. Strategic Implications

3. Market Outlook

Sources: Glenmark Pharmaceuticals, Economic Times